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AbsTRACT
Objective To determine if Allen Carr’s Easyway to Stop 
Smoking (AC) was superior to  Quit. ie in a randomised 
clinical trial (RCT).
setting Single centre, open RCT, general population 
based.
Participants 300 adult smokers, 18 years plus, 
minimum 5 cigarettes daily, and English speaking. AC, 
151 (females 44.4%) and  Quit. ie, 149 (females 45.6%), 
mean age 44 years. outcomes for all 300 were analysed 
(intention-to-treat). Recruited through advertisement 
from July 2015 to February 2016.
Intervention Randomly assigned to AC (n=151) and  
Quit. ie (n=149), matched for age, sex and education. 
Block randomisation, enrolment and follow-up at 1, 3, 
6 and 12 months. Primary aim was to determine if AC 
had higher quit rates than  Quit. ie service at 3 months. 
Secondary aims: quit rates at 1, 6 and 12 months and 
analysis of associated factors including weight. AC 
consisted of a 5-hour seminar, in a group setting.  Quit. ie 
is an online portal for smoking cessation.
Results AC had higher quit rates at 1, 3, 6 and 12 
months. AC: 38%, (n=57), 27% (n=40), 23% (n=35), 
22% (n=33) vs  Quit. ie: 20% (n=30), 15% (n=22), 15% 
(n=23), 11% (n=17), respectively (all p values <0.05). 
Logistic regression AC vs  Quit. ie, OR 2.26 (95% CI 1.22 
to 4.21) p value=0.01. Weight gain 3.8 kg in AC vs 1.8 
kg in  Quit. ie (p value <0.05).
Conclusions All AC quit rates were superior to  
Quit. ie, outcomes were comparable with established 
interventions.
Trial registration number ISRCTN12951013. 
Recruitment July 2015–February 2016.
InTROduCTIOn
Established, effective and cost-effective treatments 
for tobacco dependence include brief interven-
tion, psychological support and pharmacotherapy, 
including nicotine replacement therapy (NRT), 
varenicline and bupropion, which have a high level 
of proven success in previous scientific studies.1–10 
The success rates achieved are variable but are of 
the order of 7%–31% quit at 12 months.11–13
Recently, efforts have been made to improve 
the reach and impact of smoking cessation 
services in Ireland including the implementation 
of mobile phone, internet and social media-based 
interventions.14–18
The Allen Carr method has been used for over 
30 years and is available in 150 centres in over 50 
different countries. The method claims to have 
helped more than 30 million smokers quit, with a 
90% quit rate advertised on its website.19 There has 
been very little empirical research on the efficacy 
of the AC method.20–22 The scientific basis of the 
method is also unclear.20 AC does not include phar-
macotherapy, and the behavioural intervention 
does not seem to be based on the transtheoretical 
model of behaviour change.19 23
In this study, we compare Allen Carr’s Easyway 
to Stop Smoking (AC) with the National Online 
Smoking Cessation Service,  Quit. ie, in a randomised 
clinical trial (RCT).
sTudy ObjeCTIves
The objectives were: to assess the relative effec-
tiveness of AC and  Quit. ie, using carbon monoxide 
(CO) validated Quit status at 1, 3, 6 and 12 months 
for each treatment condition, and to measure the 
continuous abstinence rate using Russell standard,24 
to consider non-quit outcomes and factors associ-
ated with successful quitting.
sTudy gOAls
To provide an evidence base with regard to the 
efficacy of the AC method for smoking cessation 
for smokers wishing to quit and also to inform 
policy-makers regarding its possible suitability for 
inclusion in publicly recommended smoking cessa-
tion treatment services.
MeThOds
This study is an open, single-centre, randomised, 
superiority clinical trial with parallel group design 
using Consolidated Standards of Reporting Trials 
guidelines (online supplementary file 1). Patients 
(n=300) were randomly assigned to either AC 
condition or registered on the online Health Service 
Executive (HSE) National Smoking Cessation 
Service (https://www. quit. ie/).
The study protocol (online supplementary file 2) 
was registered on the ISRCTN registry.
ReCRuITMenT
Smokers were recruited through public adver-
tisement in an Irish national newspaper, and 
on national and local radio in July 2015. Those 
responding were directed to TobaccoFree Research 
Institute Ireland (TFRI) website (www. tri. ie) and 
asked to complete a study questionnaire on inclu-
sion and exclusion criteria and a readiness to quit 
score (online supplementary file 3).24
The inclusion criteria were that participants be 
18 years or older, smoking a minimum of 5 ciga-
rettes per day, have a good knowledge of the English 
language, as AC was delivered in English, and agree 
to attend all five study visits in TFRI, Dublin. Exclu-
sion criteria were doctor-diagnosed, acute cardiac 
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and must not be currently undergoing treatment for alcohol or 
illicit drug use. A total of 3065 smokers responded, 112 did not 
leave contact details, 918 were excluded on exclusion criteria. 
The remaining 2035 were contacted by email on a first-come-
first-served basis; 1414 did not respond and 631 responded posi-
tively. Appointments were sent to 551 yielding 300 who met the 
criteria, and were randomised; 251 did not attend as requested 
and 70 were not contacted once recruitment was completed in 
February 2016. Follow-up was completed in March 2017. Irish 
and UK white nationals made up 90% of the sample, nine other 
nationalities were represented and there was equal ethnic distri-
bution for both conditions.
RAndOMIsATIOn
Block randomisation was used to reduce bias and achieve balance 
in the allocation of participants to the treatment arms.25 Rando-
misation was performed by TFRI from July 2015 to February 
2016. Participants were randomised by submitting details of 
their gender, age and highest education level reached that is, 
primary, secondary or third level, resulting in eight blocks and 
consented participants within each block were then randomly 
assigned to either the AC or the  Quit. ie condition.
Participants were told that those who attended all four 
follow-up visits would be entered into a prize draw for 2-week 
holiday, a weekend holiday and an iPad.
Randomised participants were given a unique participant 
identifier code. All participant and project data were deidenti-
fied and stored on a secured password-protected server. Of the 
300 enrolled, 151 smokers were allocated to AC arm and 149 to 
Quit. ie (table 1).
deTAIls Of TReATMenT COndITIOns
Allen Carr’s easyway to stop smoking
The AC condition was delivered, free of charge, by experienced 
AC therapists.
Participants completed a 5-hour, group AC seminar, maximum 
20 participants, in a routine seminar session. Participants smoke 
during smoking breaks until there is a ritualistic final ciga-
rette followed by a 20 min relaxation exercise. Follow-up was 
arranged at TFRI research centre for months 1, 3, 6 and 12. Two 
free AC follow-ups were also available.
 Quit. ie service
 Quit. ie is an online portal for HSE smoking cessation services, 
and it is delivered free of charge.18  Quit. ie has a team of accred-
ited National Centre for Smoking Cessation and Training 
(NCSCT, UK) Tobacco Cessation Practitioners. They give 
smokers information and behavioural support on the phone, by 
text and online through their website and Facebook community. 
As part of the  Quit. ie quit plan, participants set their quit date, 
requested daily support texts and or emails for 1 month and at 
least two further follow-up communications and arranged to 
have a counselling phone call from the quit team specialist. The 
decision to use medication rested with the client, who was also 
responsible for arranging the purchase or prescription of any 
NRT or other medication that they used.
Participants were registered on  Quit. ie during their first 
TFRI visit, and an agreed quit date was set. An appointment for 
follow-up was arranged at the TFRI research centre at months 1, 
3, 6 and 12 following their target quit date. All registered clients 
are sent an email from  Quit. ie at 3 months requesting confirma-
tion of quit status.
fOllOw-uP vIsITs
All randomised smokers were invited to attend an initial and 
four other visits at TFRI. Self-reported quitting was recorded 
and validation by CO Breath test was carried out at each visit 
using a CO monitor. The monitor used in this study was the Care 
fusion CO monitor.26 Other data collected included weight, 
relapse information, medication used, motivational contacts 
received by phone, text and email or at face-to-face meetings, if 
any, or attendance at AC at each visit.
sAMPle sIze CAlCulATIOn
The quit rates at 3 months were predicted as 25% for AC and 
12% for  Quit. ie. An allocation of 1:1 was selected. With 80% 
power and two-sided significance level of 5%, a sample size 
of 139 for each group would be needed to detect superiority 
between AC and  Quit. ie.
An ‘intention-to-treat’ (ITT) approach, where only CO-vali-
dated quitting, as per Russell standard is accepted as valid was 
used to determine the numerator in both conditions and data 
from all 300 randomised smokers (149  Quit. ie and 151 Allen 
Carr) were included in the denominators for the analysis.24 
Participants who were consented, randomised, set a quit date 
on  Quit. ie or made an appointment for an AC seminar were 
included in the ITT analysis. All missing quit data were regarded 
as being due to failure to quit smoking even if the participants 
were lost to follow-up.
A complete case analysis (CCA) approach based on both 
CO-validated quitting (Russell Standard) and self-reported quit-
ting was subsequently used to examine the difference in the 
retention rate in the two conditions and reassure that failure to 
return for follow-up in person was indicative of failure to quit in 
this trial. Subjects who did not attend for follow-up in person, 
but responded to contact by email/text/phone and self-reported 
on their quit status were combined with those who had attended 
in person to form the CCA samples.
Table 1 Baseline characteristics of participants by treatment groups
Quit.ie (n=149) AC (n=151)
Female, n (%) 68 (45.6) 67 (44.4)
Age, median (IQR) 44.0 (38.0–51.0) 44.0 (36.0–52.0)
Initial weight, median (IQR), kg 80.8 (69.0–93.9) 79.8 (69.4–91.7)
Postsecondary and higher education, 
n (%)
104 (69.8) 105 (69.5)
Baseline CO reading, mean (SD), ppm 20.4 (10.5) 22.1 (11.6)
Time to first cigarette, n (%)
  ≤5 min 42 (28.2) 56 (37.1)
  6–30 min 66 (44.3) 61 (40.4)
  >31 min 41 (27.5) 34 (22.5)
Prior use of e-cigarettes, n (%) 72 (48.3) 75 (49.7)
Previous quit attempts, n (%)
  None 6 (4.2) 4 (2.7)
  1–3 63 (43.8) 69 (46.3)
  4–9 61 (42.4) 59 (39.6)
  10 and over 14 (9.7) 17 (11.4)
No of cigarettes smoked per day, 
median (IQR)
20.0 (15.0–22.0) 20.0 (15.0–25.0)
How many years are you smoking, 
median (IQR)
28.0 (22.0–34.0) 26.0 (20.0–35.0)
Readiness to quit score, median (IQR) 27.0 (24.5–29.0) 27.0 (25.0–29.0)
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The CCA numerators for quit rates, when accepting self-re-
port as quit, were the sums of self-reported quit data collected 
from those who attended in person and quit data from non-at-
tenders who responded to electronic contact. The CCA numer-
ator, when using CO-valditated quitting, can only be based on 
those who attended in person. This may be clinically misleading 
as it demands omitting self-reported quitting but is included 
for completeness. The denominators in CCA consisted of those 
for whom data were furnished in contrast to the ITT approach 
where all subjects in the trial were retained in the denominator 
even if lost to follow-up. For comparison, an ITT analysis using 
self-report quit rates was also performed.
sTATIsTICAl AnAlysIs
Analysis of variance test was used to test if participants’ categor-
ical characteristics were balanced between the two conditions. 
Two-sided two-sample mean tests were carried out for contin-
uous characteristics. In addition, as it was a superiority clinical 
trial, two-sample one-tailed proportion tests were carried out 
when comparing quit rates and retention rates between the two 
trial groups, and when comparing treatment effects in  Quit. ie. 
Two-sample mean tests were used to compare weight gain.
The dichotomous primary outcomes were analysed via multi-
variable logistic regression. The independent variables included 
were trial group, gender, education, age, prior use of e-ciga-
rettes, baseline CO reading, time to first cigarette, readiness to 
quit score and previous quit attempt. Univariable logistic regres-
sions were carried out to measure the impact on quit outcome of 
taking cigarette puffs between visits. Significance level of all tests 
was set to 0.05. All analyses were performed using IBM SPSS 
Statistics for Windows V.24.
ResulTs
Χ2 test and two-sample proportion z test showed that AC was 
superior to  Quit. ie. At each visit, the quit rate in the AC group 
is significantly greater than that of the  Quit. ie group using ITT 
Co-validated quitting (table 2). The difference between the two 
groups was strongest at the 1-month follow-up visit and remained 
statistically significant at 3, 6 and 12-month follow-ups, in each 
of which, quit rates in the AC group were almost twice that of 
the  Quit. ie. Table 2 shows that in the AC condition, the quit rate 
decreased from 37.7% (n=57) at 1 month to 21.9% (n=33) at 
12 months (p=0.001) while in  Quit. ie, the quit rate decreased 
from 20% (n=30) at 1 month to 11.4% (n=17) at the 12 months 
(p=0.02).
Using CCA and CO-validated quitting, where the quitting rate 
in AC was nearly twice as great as  Quit. ie, the difference was not 
statistically significant.
It was assumed in ITT that non-attenders had mainly failed to 
quit, no such assumption was made for CCA and that seemed to 
account for the difference in attendance in this trial.
However, using data collected from non-attenders and 
accepting self-report as quit for ITT and CCA, the results were 
similar to CO-validated quitting ITT with an even greater supe-
riority for AC and suggesting that failure to attend was not 
attributable to the condition (table 2) and that the worst case 
assumption of CO-validated quitting was not misleading.
The relapse rates were not significantly different between 
Quit. ie and AC condition at the 1, 3, 6 or 12 month visits.
Multivariate logistic regression of 3-month outcomes 
included: trial group, gender, education, age, prior use of E-cig-
arettes, baseline CO reading, time to first cigarette, readiness to 
quit score and previous quit attempts. Three significant variables 
were found: trial group, education and baseline CO.
Being in the AC condition increased the odds of quitting by 2.3 
(95% CI 1.2 to 4.2) compared with being in  Quit. ie condition. 
Education and baseline CO level were also significant factors 
associated with an increased likelihood of quitting at 3-month 
follow-up (table 3).
In sensitivity analysis, CO readings were replaced by the 
number of cigarettes smoked per day; this was not found to be 
significant. The number of years’ participants were smoking 
was not included as the correlation of number of years smoking 
with age was too strong. Time to first cigarette variable had two 
missing values, and previous quit attempt variable had seven 
missing values. Therefore, the total number of observations used 





P values*no of quitters sample size Quit rate no of quitters sample size Quit rate
ITT Russell 
Standard
1 30 149 20.1% 57 151 37.7% <0.001†
3 22 149 14.8% 40 151 26.5% 0.006†
6 23 149 15.4% 35 151 23.2% 0.045†
12 17 149 11.4% 33 151 21.9% 0.008†
Self-report 1 36 149 24.2% 63 151 41.7% <0.001†
3 26 149 17.5% 48 151 31.8% 0.002†
6 25 149 16.8% 42 151 27.8% 0.011†
12 21 149 14.1% 36 151 23.8% 0.016†
CCA Russell 
Standard
1 30 69 43.5% 57 110 51.8% 0.139
3 22 46 47.8% 40 81 49.4% 0.433
6 23 41 56.1% 35 72 48.6% 0.778
12 17 38 44.7% 33 63 52.4% 0.228
Self-report 1 36 124 29.0% 63 134 47.0% 0.002†
3 26 114 22.8% 48 130 36.9% 0.008†
6 25 108 23.1% 42 120 35.0% 0.025†
12 21 105 20.0% 36 107 33.6% 0.013†
*The alternative hypothesis is that AC has a higher quit rate than Quit.ie.
†The test is significant at 0.05 level.
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in the final regression was 291 instead of 300. Regressions were 
also run for 1 month, 6 months and 12 months. Trial group and 
education remained significant for all months. CO level was 
significant at 1 and 6 months but not at 12 months.
Smokers with higher education had 3.6 (95% CI 1.6 to 8.3) 
times’ greater odds of quitting than those with lower education 
(table 3). The quit rate was greater in the AC higher education 
group at each month and statistically significant at 1, 3 and 12 
months. For people with lower education, the quit rate was 
also greater in the AC group at each month, but the numbers 
in this category were small and did not reach statistical signifi-
cance (table 4). There was a lower number of those with a lower 
education recruited, n=92 versus higher educated n=209, at 
least partially explained by completion rates for second-level 
education in Ireland of 91%.27
A 1-unit increase in baseline CO reading was associated with 
95.5% (95% CI 92% to 99%) lower odds of quitting. Variables 
to measure the extent of addiction, before participants started 
the trial, were: how soon after waking they had their first ciga-
rette, years of smoking and the number of cigarettes smoked per 
day.28 After replacing the CO reading variable by the alternatives 
one at a time, the alternatives were not significant at 0.05 levels 
while trial groups and education remained significant.
All participants were asked to self-report their quit status 
at each visit, and breath CO tests were performed. Nobody 
in either condition self-reporting quit at 3 months had a CO 
reading >5. In the  Quit. ie condition, one participant reporting 
quit at 12 months had a CO reading of >10. In the AC condi-
tion, one participant who reported quit at 12 months had a CO 
reading between 6 and 10 recorded.
The relationship between having taken a ‘single puff ’ between 
quit date and 1 month and quit outcome at subsequent visits 
was also examined combining both trial groups. Univariable 
logistic regressions were carried out and were significant at both 
3-month and 6-month visits. People who had quit at 1 month 
who had not taken a single puff (n=65) between quit date and 
1 month had a 3.9 (95% CI 1.4 to 11.2) times greater odds of 
quitting at 3 months (n=47) than those who had taken a puff at 
1 month (n=20) and had quit at 3 months (n=10).
All participants attending the AC condition were instructed 
not to take any form of pharmacotherapy to aid quitting. There-
fore, when considering the pharmacotherapeutic agents used 
for quitting, other than e-cigarettes, we examined only  Quit. ie. 
This showed: NRT (n=42, various formulations), varenicline 
(n=14) and none (n=14). Those who took varenicline between 
quit date and 3 months had a significantly higher quit rate at 3 
months than both those who took nothing (p=0.003) and those 
who took NRT (p=0.005). There was no statistically significant 
difference in quit outcome at 3 months between those using 
none and those using NRT (p=0.36).
A number of participants used e-cigarettes at some stage 
between quit date and 3 months, (n=15) in  Quit. ie and (n=12) 
in the AC condition. E-cigarettes were not found to significantly 
affect the quit outcome at 3 months in AC group. In  Quit. ie 
condition, people who used e-cigarettes before the 3-month visit 
achieved a lower quit rate at 3 months (3 out of 15) than those 
who did not use e-cigarettes (19 out of 35) (p=0.01). This result 
may be due to the small number of observations in  Quit. ie.
Successful quitters gained weight in both study conditions. 
There were three pregnant women in the study, two in AC group 
and one in  Quit. ie. There were two participants who had serious 
illnesses and received medical intervention during the study. As 
fluctuations in weight could not be attributed to quitting, all five 
were removed from the weight analysis.
Absolute weight gains: The mean weight gain for quitters at 3 
months in AC was 3.8 kg vs 1.8 kg in  Quit. ie, the mean weight 
gain at 12 months in the AC was 5.02 kg vs 3.18 kg in  Quit. ie. 
The mean weight gain was statistically greater in AC than  Quit. 
ie at 1, 3 and 6 months (p=0.003 for 1 month, p=0.008 for 3 
months, p=0.02 for 6 months), but not at 12 months (p=0.15).
Of the 300 participants randomised, the numbers retained at 
1, 3, 6 and 12 months were 179, 127, 113 and 101 participants, 
respectively. The retention rate was significantly higher in the 
AC group than that in the  Quit. ie group at each follow-up visit 
(p<0.001 at 1, 3 and 6 months, p=0.002 at 12 months). To 
get further information on the quit rates including non-attenders 
at clinic follow-up, all participants who did not attend at each 
month were contacted by email or by phone, if no email address 
was available. A CCA was then performed on the total sample 
with quit data at 1 month, 258 total (124  Quit. ie vs 134 AC), at 
3 months 244 (114  Quit. ie vs 130 AC), at 6 months 228 (108 
Quit. ie vs 120 AC) and at 12 months 212 (105  Quit. ie vs 107 
AC). This analysis showed that AC was statistically superior at 
each month, with p value at 0.002, 0.008, 0.025 and 0.013 at 1, 
3, 6 and 12 months, respectively (see online online supplemen-
tary file 4).
The only reported adverse effect was one person in the AC 
treatment who went to see her doctor because of withdrawal 
symptoms.
dIsCussIOn
In this RCT, AC—a non-pharmacotherapeutic one-off semi-
nar-based intervention—had a quit rate which was superior to 
Table 3 Logistic regression of 3-month outcome
95% CI for OR
P values OR lower upper
AC (vs Quit.ie) 0.01 2.26 1.22 4.21
Female (vs male) 0.94 1.03 0.55 1.92
Higher (vs lower) education 0.002 3.62 1.58 8.28
Age 0.89 1.00 0.97 1.04
Prior use of e-cigarette (vs non-use) 0.93 0.97 0.52 1.82
Baseline CO reading 0.005 0.96 0.92 0.99
Time to first cigarette (vs ≤5 min) 0.42
  6–30 min 0.19 0.61 0.29 1.28
  >31 min 0.61 0.80 0.35 1.86
Readiness to quit score 0.95 1.00 0.91 1.09
Previous attempts to quit (vs none) 0.10
  1–3 0.51 2.11 0.23 19.01
  4–9 0.33 2.90 0.32 26.33
  10+ 0.11 6.72 0.66 68.22
Constant 0.16 0.07
AC, Allen Carr’s Easyway to Stop Smoking; CO, carbon monoxide.




AC higher Quit.ie higher AC lower Quit.ie lower
 n (%) n (%) n (%) n (%)
1 45 (43) 27 (26) 12 (26) 3 (7)
3 34 (32) 20 (19) 6 (13) 2 (4)
6 29 (28) 20 (19) 6 (13) 3 (7)
12 27 (26) 15 (14) 6 (13) 2 (4)
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an online comprehensive national smoking cessation service 
consisting of advice by telephone, texts and email, supported by 
a dedicated website and Facebook community.
The short-term and long-term cessation CO-validated quit 
rates of AC exceeded those of  Quit. ie by a factor of nearly two 
at all the time points tested on an ITT basis. The mechanism of 
this effect is unclear. There is some suggestion that the seminar 
is based on an expectancy challenge as has been used in alcohol 
treatment and consideration of these types of interventions seem 
to be similar to the AC approach.20 29–31 Being told that all AC 
therapists have used the method to stop smoking themselves, 
the widespread celebrity endorsements, and the popularity of 
the Allen Carr book may also be factors. The recent RCT of 
the Allen Carr book does not seem to support this latter sugges-
tion.32 It specifically does not seem to be based on motivational 
behavioural change, and smoking cessation pharmacotherapy is 
not allowed or suggested even for control of withdrawal symp-
toms. No apps, texts or phone calls or social media community 
are prescribed in AC. The results achieved with AC, 26% quit at 
12 months, are similar to the estimates for UK national smoking 
cessation service for varenicline with specialist individual 
behavioural support at a specialist clinic.(13) The results achieved 
with  Quit. ie at 11% at 12 months are similar to UK national 
smoking cessation service with Mono NRT with specialist 
drop-in behavioural support.1 13
The outcomes in  Quit. ie are comparable with results observed 
with individual elements of successful interventions of internet, 
telephone support, emails and social media. Perhaps  Quit. ie may 
be improved by increased use of proven evidence-based medica-
tion and face to face consultations. 17 33
This RCT was limited to well people and although there was 
no age restriction in the protocol, it did not have very many 
young adults or older people who may have a lower quit rate but 
this did not seem to increase the quit rate in the well-matched 
Quit. ie condition. Our inability to explore possible mechanisms 
of action of AC and the training of AC therapists and not to be 
able to tailor  Quit. ie content precisely creates a limitation to full 
understanding of the conditions but does not account for the 
superiority of the AC condition. For instance, face-to-face inter-
actions were possible in the  Quit. ie service but must be requested 
by the participant and they were not requested. Also pharmaco-
therapy was recommended in  Quit. ie but was underused within 
the programme by trial participants. Changes have been made to 
formalise the interventions in the  Quit. ie service. 
The retention rate was low, particularly in the  Quit. ie condi-
tion and may have been partially influenced by the absence 
of personal contact. Electronic follow-up of clinic defaulters 
confirmed a lower self-reported quit rate in  Quit. ie. The resulting 
CCA analysis gave similar results to the ITT approach suggesting 
that the poor retention rate was not particular to either condi-
tion and did not materially affect the results.
One person in the AC condition developed significant with-
drawal symptoms which led her to visit her doctor. Otherwise, 
AC was very well tolerated, making it particularly suitable for 
smokers unwilling or unable to tolerate pharmacotherapy. Preg-
nancy is also a condition where AC would seem particularly 
suitable, where reluctance to take medication is very strong.34 35 
Young people who also have a low uptake of present services may 
be interested in the AC method.36–38 These are populations not 
addressed in this trial but would seem worthy of further explo-
ration. It is clear however that it is suitable for well, middle-aged 
smokers of both sexes.
There is widespread acceptance by the public of the efficacy 
of AC as evidenced by the numbers who have used the service at 
their own expense and its widespread use in corporate settings 
for smoking cessation but, to the best of our understanding, it is 
not employed by any public health agency providing a smoking 
cessation service.19 The previous lack of RCT evidence showing 
efficacy may be the reason funding authorities both public and 
private seem reluctant to offer AC. The present RCT is positive 
and should encourage further trials and increase the likelihood 
that AC will take its place as a valid, effective and needed addi-
tion to available smoking cessation interventions.
what this paper adds
 ► The Allen Carr book is said to have sold some 13 million 
copies and have helped people stop smoking.
 ► There are a large number of celebrity endorsements testifying 
to the merits of Allen Carr’s method but very few trials of any 
kind and very few publications of outcomes.
 ► No randomised clinical trials of Allen Carr’s Easyway to Stop 
Smoking were published before this trial.
 ► This study shows that Allen Carr’s Easyway to Stop Smoking 
was superior to a standard online National Smoking 
Cessation in a Randomised Clinical Trial.
 ► It was free of any serious side effects.
 ► As a once-off seminar, where pharmacotherapy is not used, 
it seems highly appropriate to consider it as an acceptable 
method for smoking cessation.
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